Shopping Cart
- Remove All
 
Your shopping cart is currently empty
BKIDC-1553, an orally active antiglycolytic agent and bumped kinase inhibitor-derived compound, has a predicted half-life of approximately 17 hours in humans. It inhibits CYP2C8 and Angiotensin Converting Enzyme, making it suitable for cancer research [1].

| Pack Size | Price | Availability | Quantity | 
|---|---|---|---|
| 25 mg | $1,520 | 6-8 weeks | |
| 50 mg | $1,980 | 6-8 weeks | |
| 100 mg | $2,500 | 6-8 weeks | 
| Description | BKIDC-1553, an orally active antiglycolytic agent and bumped kinase inhibitor-derived compound, has a predicted half-life of approximately 17 hours in humans. It inhibits CYP2C8 and Angiotensin Converting Enzyme, making it suitable for cancer research [1].  | 
| In vitro | BKIDC-1553 (1.25-20 μM, 72 h) inhibits cell proliferation in various human prostate cancer cell lines in a dose-dependent manner [1].  | 
| In vivo | BKIDC-1553, administered orally at 20 mg/kg three times per week for four weeks, reduces tumor growth in LuCaP 35 patient-derived xenograft mice with human prostate cancer after five weeks [1].  | 
| Molecular Weight | 389.45 | 
| Formula | C22H23N5O2 | 
| Cas No. | 1951431-34-7 | 
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | 

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.